DeutschNewstral
Article
Mmarketwatch.com on 2020-07-08 14:46
Biogen's stock rises on submission to FDA for Alzheimer's drug application
Related news
- MBiogen's stock rallies 11% after FDA accepts application for experimental Alzheimer's drugmarketwatch.com
Biogen's Alzheimer's drug wins FDA approvalbizjournals.com
FDA approval of Biogen's Alzheimer's drug leaves some 'disappointed'Fox News- BFDA Approves Eisai and Biogen's New Alzheimer's Therapy 1 min readbarrons.com
- BFDA Narrows Its Label on Biogen's Alzheimer's Drug a Month After Approving It3 min readbarrons.com
- BThe FDA Decision on Biogen's Alzheimer's Drug Is Almost Here. What Investors Need to Know.barrons.com
- All eyes on Biogen's experimental Alzheimer's drug as FDA deadline nearsbizjournals.com
- 2 FDA advisers, including Washington U professor, resign after Biogen's drug approved for Alzheimer'sbizjournals.com
- MFDA calls for investigation into its own approval of Biogen's Alzheimer's drug2 min readmarketwatch.com
- The Petri Dish: FDA to fast-track Biogen's next Alzheimer's drugbizjournals.com
- Biogen's drug approval in Alzheimer's spurs two FDA advisers to resignbizjournals.com
- BAcknowledging Concerns Over Biogen's Alzheimer's Drug, FDA Asks for Investigation2 min readbarrons.com
- BTop FDA Staffers Defend Approval of Biogen's Alzheimer's Drug 4 min readbarrons.com
- Medicare severely restricts Biogen's Alzheimer's drug coveragebizjournals.com
- How RTP plays critical role for Biogen's blockbuster Alzheimer's drugbizjournals.com
- BThe $56,000 Price of Biogen's Alzheimer's Drug Could Backfire4 minbarrons.com
- Biogen's other Alzheimer's drug fails in late-stage trialbizjournals.com